ICML 2025 | Updated findings from a Phase I/II study of golcadomide plus rituximab in R/R DLBCL

I was glad to present the results on behalf of my co-author from the golcadomide study in combination with rituximab in relapsed/refractory diffuse large B-cell lymphoma. This data has been already presented in previous meetings, but has been updated with longer follow-up. So this is a large study with a monotherapy combination and here I was reporting specifically on the subcohort C of part B of the trial which concerned only patients with relapsed/refractory large B-cell lymphoma after two lines of previous treatment or after one line of previous treatment but ineligible for stem cell transplant so overall 77 patients have been enrolled with large B-cell lymphoma the median age is 66 years and the patients were heavily pretreated. 55% of them received previous CAR T-cells which is high. One third of them received previous bispecific antibodies so heavily pretreated patient population. The treatment schedule was 0.2 or 0.4 milligram of golcadomide on the 14 days on 14 days off schedule in combination with rituximab. The safety profile is really good. The only toxicity is any grade and grade 3-4 neutropenia occurring in 64% of the patients. It usually occurs during the first cycles of treatment and usually with GCSF the duration is very short so very manageable toxicity of the compound. In terms of efficacy the overall response rate is nearly 60% in the 0.4 mg golcadomide cohort with 44% of complete response. So very encouraging results with a safety profile that is really good and the drug is moving forward in large phase three trial in DLBCL in frontline with the GOLSEEK-1 study and the relapsed refractory setting in follicular lymphoma with the GOLSEEK-4 study.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.